The use of drug-receptor affinity measures in the differentiation of receptors

The drug-receptor dissociation constant (K), determined by pharmacological procedures, is measured from a dose-effect relation and the modification of that relation by the presence of a second compound (antagonist) that competes for the same receptor. These procedures differ from those that use radi...

Full description

Bibliographic Details
Published in:Federation proceedings, Vol. 41, No. 7 (1982), p. 2323-7
Main Author: Tallarida, R J
Format: Article
Language:English
ISSN:0014-9446
Item Description:Date Completed 19.07.1982
Date Revised 21.11.2013
published: Print
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Subjects:
QR Code: Show QR Code
LEADER 04401naa a2200769 c 4500
001 NLM060998679
003 DE-601
005 20181224224649.0
008 180202s1982 000 0 eng d
028 5 2 |a pubmed19n0204.xml 
035 |a (DE-599)NLM6122613 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Tallarida, R J 
245 1 4 |a The use of drug-receptor affinity measures in the differentiation of receptors 
500 |a Date Completed 19.07.1982 
500 |a Date Revised 21.11.2013 
500 |a published: Print 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a The drug-receptor dissociation constant (K), determined by pharmacological procedures, is measured from a dose-effect relation and the modification of that relation by the presence of a second compound (antagonist) that competes for the same receptor. These procedures differ from those that use radiolabeled compounds and do not measure an effect but instead determine the K of the compound by quantitating its displacement of the labeled substance. In several examples the dissociation constants determined from pharmacological procedures are shown to be unique for a particular drug-receptor interaction and can therefore discriminate among receptors. A further demonstration is that K does not equal D50, the potency index. For competitive antagonists the Schild plot is commonly used to measure K. This plot, theoretically linear with a slope of -1, often leads to slopes different from -1 (using conventional linear regression), in which case its x intercept, pA2, and y intercept, -log KB, differ by an amount that depends on the slope. Even when this differences is small, the 95% confidence limits of pA2 and -log KB may be very different and are invariably larger for -log KB, the value that is presumably sought from this analysis. A Schild plot constrained to slope -1 (and, accordingly, different regression equations) should therefore be used in cases of known competitive antagonism such as that between naloxone and morphine. The special problems associated with measuring K for agonists are discussed and illustrated with recent work done in our laboratories in which we employed the new narcotic analgesic buprenorphine to determine by pharmacological methods the dissociation constant for morphine, a value previously undetermined 
611 2 7 |a Journal Article  |2 gnd 
611 2 7 |a Research Support, U.S. Gov't, P.H.S.  |2 gnd 
653 2 |a Adrenergic alpha-Agonists  |6 D000316  |a metabolism  |6 Q000378 
653 2 |a Animals  |6 D000818 
653 2 |a Dose-Response Relationship, Drug  |6 D004305 
653 2 |a *Drug Antagonism  |6 D004336 
653 2 |a Ethanolamines  |6 D004983  |a pharmacology  |6 Q000494 
653 2 |a Isoproterenol  |6 D007545  |a antagonists & inhibitors  |6 Q000037 
653 2 |a Mathematics  |6 D008433 
653 2 |a Morphine  |6 D009020  |a antagonists & inhibitors  |6 Q000037  |a pharmacology  |6 Q000494 
653 2 |a Naloxone  |6 D009270  |a pharmacology  |6 Q000494 
653 2 |a Rabbits  |6 D011817 
653 2 |a Rats  |6 D051381 
653 2 |a Receptors, Adrenergic, alpha  |6 D011942  |a metabolism  |6 Q000378 
653 2 |a Receptors, Drug  |6 D011955  |a *metabolism  |6 Q000378 
653 2 |a Receptors, Opioid  |6 D011957  |a metabolism  |6 Q000378 
655 7 |a Adrenergic alpha-Agonists  |2 gnd 
655 7 |a Ethanolamines  |2 gnd 
655 7 |a Receptors, Adrenergic, alpha  |2 gnd 
655 7 |a Receptors, Drug  |2 gnd 
655 7 |a Receptors, Opioid  |2 gnd 
655 7 |a Naloxone  |2 gnd 
655 7 |a 36B82AMQ7N  |2 gnd 
655 7 |a Morphine  |2 gnd 
655 7 |a 76I7G6D29C  |2 gnd 
655 7 |a Isoproterenol  |2 gnd 
655 7 |a L628TT009W  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 1 |A f  |a Research Support, U.S. Gov't, P.H.S. 
689 0 |5 DE-601 
689 2 0 |a Adrenergic alpha-Agonists 
689 2 1 |a Ethanolamines 
689 2 2 |a Receptors, Adrenergic, alpha 
689 2 3 |a Receptors, Drug 
689 2 4 |a Receptors, Opioid 
689 2 5 |a Naloxone 
689 2 6 |A r  |a 36B82AMQ7N 
689 2 7 |a Morphine 
689 2 8 |A r  |a 76I7G6D29C 
689 2 9 |a Isoproterenol 
689 2 X |A r  |a L628TT009W 
689 2 |5 DE-601 
773 0 8 |i in  |t Federation proceedings  |g Vol. 41, No. 7 (1982), p. 2323-7  |q 41:7<2323-7  |w (DE-601)NLM000050148  |x 0014-9446 
912 |a GBV_NLM 
951 |a AR 
952 |d 41  |j 1982  |e 7  |c 05  |h 2323-7